Literature DB >> 25932197

Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus.

Ligia Petrica1, Adrian Vlad2, Gheorghe Gluhovschi1, Alina Zamfir3, Cristina Popescu4, Florica Gadalean1, Victor Dumitrascu5, Daliborca Vlad5, Roxana Popescu6, Silvia Velciov1, Cristina Gluhovschi1, Flaviu Bob1, Oana Milas7, Sorin Ursoniu8.   

Abstract

BACKGROUND: Advanced glycation end-products have been involved in the pathogenesis of proximal tubule dysfunction which characterizes diabetic tubulopathy.
METHODS: A total of 76 Type 2 diabetes mellitus patients and 28 healthy controls were evaluated concerning a potential association of glycated peptides with proximal tubule dysfunction by assessing urine albumin:creatinine ratio, urinary alpha1-microglobulin, urinary neutrophil gelatinase-associated lipocalin, plasma and urinary advanced glycation end-products, plasma asymmetric dimethyl-arginine, serum cystatin C. Fully automated chip-nanoelectrospray ionization and high-capacity ion trap multistage mass spectrometry characterized the urinary proteomic profile.
RESULTS: The urinary glycated proteins displayed a molecular weight of 15,121.4 Da in normoalbuminuric patients and of 30,180.4 Da in microalbuminuric patients. Urinary alpha1-microglobulin and neutrophil gelatinase-associated lipocalin correlated with urinary advanced glycation end-products (R(2)=0.586; R(2)=0.415), urine albumin: creatinine ratio (R(2)=0.292; R(2)=0.116), estimated glomerular filtration rate (R(2)=0.172; R(2)=0.135), serum cystatin C (R(2)=0.146; R(2)=0.129), but not with asymmetric dimethyl-arginine. In multivariable regression analysis models, the correlations for urinary alpha1-microglobulin and neutrophil gelatinase-associated lipocalin remained significant with urine albumin: creatinine ratio, urinary advanced glycation end-products, estimated glomerular filtration rate (P<0.0001, R(2)=0.674; P<0.0001, R(2)=0.551; P<0.0001, R(2)=0.482).
CONCLUSIONS: In patients with Type 2 diabetes mellitus urinary glycated peptides are associated with proximal tubule dysfunction. The proteomic patterns of urinary glycated peptides could differentiate normo- from microalbuminuric patients and may explain a potential relation between the size and the glycation status of glycated peptides, and the extent of proximal tubule dysfunction. The lack of correlation between parameters of endothelial dysfunction and proximal tubule dysfunction cannot exclude glomerular involvement in early diabetic nephropathy.

Entities:  

Keywords:  Glycated peptides; Type 2 diabetes mellitus; normoalbuminuria; proximal tubule

Year:  2015        PMID: 25932197      PMCID: PMC4402844     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  30 in total

1.  Assessment of the molecular expression and structure of gangliosides in brain metastasis of lung adenocarcinoma by an advanced approach based on fully automated chip-nanoelectrospray mass spectrometry.

Authors:  Alina D Zamfir; Alina Serb; Željka Vukeli; Corina Flangea; Catalin Schiopu; Dragana Fabris; Svjetlana Kalanj-Bognar; Florina Capitan; Eugen Sisu
Journal:  J Am Soc Mass Spectrom       Date:  2011-10-15       Impact factor: 3.109

2.  Kidney disease in diabetology: lessons from 2010.

Authors:  Guntram Schernthaner
Journal:  Nephrol Dial Transplant       Date:  2011-02       Impact factor: 5.992

3.  Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney.

Authors:  M-L Gross; G Piecha; A Bierhaus; W Hanke; T Henle; P Schirmacher; E Ritz
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-02

4.  Activation of tubular epithelial cells in diabetic nephropathy.

Authors:  Michael Morcos; Ahmed A R Sayed; Angelika Bierhaus; Benito Yard; Rüdiger Waldherr; Wolfgang Merz; Ingrid Kloeting; Erwin Schleicher; Stefani Mentz; Randa F Abd el Baki; Hans Tritschler; Michael Kasper; Vedat Schwenger; Andreas Hamann; Klaus A Dugi; Anne-Marie Schmidt; David Stern; Reinhard Ziegler; Hans U Haering; Martin Andrassy; Fokko van der Woude; Peter P Nawroth
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

5.  Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT).

Authors:  Elizabeth F O Kern; Penny Erhard; Wanjie Sun; Saul Genuth; Miriam F Weiss
Journal:  Am J Kidney Dis       Date:  2010-05       Impact factor: 8.860

6.  Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Authors:  E Ritz; G C Viberti; L M Ruilope; A J Rabelink; J L Izzo; S Katayama; S Ito; A Mimran; J Menne; L C Rump; A Januszewicz; H Haller
Journal:  Diabetologia       Date:  2009-10-30       Impact factor: 10.122

7.  Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes.

Authors:  Ko Hanai; Tetsuya Babazono; Izumi Nyumura; Kiwako Toya; Nobue Tanaka; Mizuho Tanaka; Akiko Ishii; Yasuhiko Iwamoto
Journal:  Nephrol Dial Transplant       Date:  2009-01-07       Impact factor: 5.992

8.  Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore.

Authors:  Ching-Ye Hong; Kenneth Hughes; Kee-Seng Chia; Vivian Ng; Sing-Lin Ling
Journal:  Diabetes Care       Date:  2003-02       Impact factor: 19.112

9.  Nonalbuminuric renal insufficiency in type 2 diabetes.

Authors:  Richard J MacIsaac; Con Tsalamandris; Sianna Panagiotopoulos; Trudy J Smith; Karen J McNeil; George Jerums
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 10.  Histopathology of diabetic nephropathy.

Authors:  Paola Fioretto; Michael Mauer
Journal:  Semin Nephrol       Date:  2007-03       Impact factor: 5.299

View more
  8 in total

1.  Association of neutrophil-gelatinase-associated lipocalin with microvascular complications in patients with type 2 diabetes: a cross-sectional study.

Authors:  Erhan Aslanhan; David Ojalvo; Ekmek Burak Özsenel; Sema Ucak Basat; Fatih Borlu
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-09-10

Review 2.  Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy.

Authors:  Cristina Gluhovschi; Gheorghe Gluhovschi; Ligia Petrica; Romulus Timar; Silvia Velciov; Ioana Ionita; Adriana Kaycsa; Bogdan Timar
Journal:  J Diabetes Res       Date:  2016-06-16       Impact factor: 4.011

3.  Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.

Authors:  Adrian Vlad; Mihaela Vlad; Ligia Petrica; Sorin Ursoniu; Florica Gadalean; Roxana Popescu; Daliborca Vlad; Victor Dumitrascu; Gheorghe Gluhovschi; Cristina Gluhovschi; Silvia Velciov; Flaviu Bob; Petru Matusz; Alina Secara; Anca Simulescu; Dragos Catalin Jianu
Journal:  Ren Fail       Date:  2016-11-13       Impact factor: 2.606

4.  Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction.

Authors:  Chunmei Xu; Xiaojun Zhou; Tianyue Xie; Yuan Zhou; Qian Zhang; Shan Jiang; Rui Zhang; Lin Liao; Jianjun Dong
Journal:  Theranostics       Date:  2020-05-22       Impact factor: 11.556

5.  Ultrasonography Combined with Blood Biochemistry on the Early Diagnosis of Diabetic Kidney Disease.

Authors:  Jing Lin; Guangde Liu; Yuxuan Lin; Chao Wei; Sujun Liu; Youhua Xu
Journal:  Dis Markers       Date:  2022-10-05       Impact factor: 3.464

Review 6.  Urinary Markers of Tubular Injury in Early Diabetic Nephropathy.

Authors:  Temesgen Fiseha; Zemenu Tamir
Journal:  Int J Nephrol       Date:  2016-05-16

7.  Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study.

Authors:  Rongzhen Wang; Can Yao; Feng Liu
Journal:  Biomed Res Int       Date:  2020-04-03       Impact factor: 3.411

Review 8.  Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD).

Authors:  Jaehyun Bae; Young Jun Won; Byung-Wan Lee
Journal:  Life (Basel)       Date:  2021-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.